Abstract
Cyclophosphamide (CPA)-based combination treatment has known to be effective for breast cancer, but often causes adverse drug reactions (ADRs). Hence, the identification of patients at risk for toxicity by CPA is clinically significant. In this study, a stepwise case–control association study was conducted using 403 patients with breast cancer who received the CPA combination therapy. A total of 143 genetic polymorphisms in 13 candidate genes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, ALDH1A1, ALDH3A1, GSTA1, GSTM1, GSTP1, GSTT1, ABCC2 and ABCC4), possibly involved in the activation, metabolism and transport of CPA, were genotyped using 184 cases who developed either ⩾grade 3 leukopenia/neutropenia or ⩾grade 2 gastrointestinal toxicity and 219 controls who did not show any ADRs throughout the treatment. The association study revealed that one SNP, rs9561778 in ABCC4, showed a significant association with CPA-induced ADRs (Cochran–Armitage trend's P-value=0.00031; odds ratio (OR)=2.06). Subgroup analysis also indicated that the SNP rs9561778 was significantly associated with two major ADR subgroups; gastrointestinal toxicity and leukopenia/neutropenia (Cochran–Armitage trend's P-value=0.00019 and 0.014; OR=2.31 and 1.83). Furthermore, the SNP rs9561778 showed an association with breast cancer patients who were treated with CA(F) drug regimen-induced ADR (Cochran–Armitage trend's P-value=0.00028; OR=3.13). The SNPs in ABCC4 might be applicable in predicting the risk of ADRs in patients receiving CPA combination chemotherapy.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Zhang, J., Tian, Q. & Zhou, S. F. Clinical pharmacology of cyclophosphamide and ifosfamide. Curr. Drug. Ther. 1, 104–168 (2006).
Pritchard, K. I., Shepherd, L. E., O’Malley, F. P., Andrulis, I. L., Tu, D., Bramwell, V. H. et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med. 354, 2103–2111 (2006).
Zhang, J., Tian, Q., Yung, C. S., Chuen, L. S., Zhou, S., Duan, W. et al. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab. Rev. 37, 611–703 (2005).
Chang, T. K., Weber, G. F., Crespi, C. L. & Waxman, D. J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 53, 5629–5637 (1993).
de Jonge, M. E., Huitema, A. D., Rodenhuis, S. & Beijnen, J. H. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet. 44, 1135–1164 (2005).
Dirven, H. A., van Ommen, B. & van Bladeren, P. J. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res. 54, 6215–6220 (1994).
Moreb, J. S., Gabr, A., Vartikar, G. R., Gowda, S., Zucali, J. R. & Mohuczy, D. Retinoic acid down-regulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroperoxycyclophosphamide and acetaldehyde. J. Pharmacol. Exp. Ther. 312, 339–345 (2005).
Qiu, R., Kalhorn, T. F. & Slattery, J. T. ABCC2-mediated biliary transport of 4-glutathionylcyclophosphamide and its contribution to elimination of 4-hydroxycyclophosphamide in rat. J. Pharmacol. Exp. Ther. 308, 1204–1212 (2004).
Tian, Q., Zhang, J., Tan, T. M., Chan, E., Duan, W., Chan, S. Y. et al. Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm. Res. 22, 1837–1853 (2005).
Zhong, S., Huang, M., Yang, X., Liang, L., Wang, Y., Romkes, M. et al. Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. Br. J. Clin. Pharmacol. 62, 457–472 (2006).
Takada, K., Arefayene, M., Desta, Z., Yarboro, C. H., Boumpas, D. T., Balow, J. E. et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum. 50, 2202–2210 (2004).
Singh, G., Saxena, N., Aggarwal, A. & Misra, R. Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus. J. Rheumatol. 34, 731–733 (2007).
Ohnishi, Y., Tanaka, T., Ozaki, K., Yamada, R., Suzuki, H. & Nakamura, Y. A high throughput SNP typing system for genome-wide association studies. J. Hum. Genet. 46, 471–477 (2001).
Bolt, H. M. & Thier, R. Relevance of the deletion polymorphisms of the glutathione S-transferases GSTT1 and GSTM1 in pharmacology and toxicology. Curr. Drug Metab. 7, 613–628 (2006).
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A., Bender, D. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
Barrett, J. C., Fry, B., Maller, J. & Daly, M. J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263–265 (2005).
Ekhart, C., Doodeman, V. D., Rodenhuis, S., Smits, P. H., Beijnen, J. H. & Huitema, A. D. Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. Br. J. Clin. Pharmacol. 67, 50–60 (2009).
Goekkurt, E., Stoehlmacher, J., Stueber, C., Wolschke, C., Eiermann, T., Iacobelli, S. et al. Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation. Anticancer Res. 27, 4377–4380 (2007).
van Aubel, R. A., Smeets, P. H., Peters, J. G., Bindels, R. J. & Russel, F. G. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol. 13, 595–603 (2002).
Torky, A. R., Stehfest, E., Viehweger, K., Taege, C. & Foth, H. Immuno-histochemical detection of MRPs in human lung cells in culture. Toxicology 207, 437–450 (2005).
Rius, M., Nies, A. T., Hummel-Eisenbeiss, J., Jedlitschky, G. & Keppler, D. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 38, 374–384 (2003).
Lee, K., Klein-Szanto, A. J. & Kruh, G. D. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J. Natl. Cancer Inst. 92, 1934–1940 (2000).
Nies, A. T., Jedlitschky, G., König, J., Herold-Mende, C., Steiner, H. H., Schmitt, H. P. et al. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 129, 349–360 (2004).
König, J., Hartel, M., Nies, A. T., Martignoni, M. E., Guo, J., Büchler, M. W. et al. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int. J. Cancer 115, 359–367 (2005).
Schuetz, J. D., Connelly, M. C., Sun, D., Paibir, S. G., Flynn, P. M., Srinivas, R. V. et al. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med. 5, 1048–1051 (1999).
Jedlitschky, G., Tirschmann, K., Lubenow, L. E., Nieuwenhuis, H. K., Akkerman, J. W., Greinacher, A. et al. The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. Blood 104, 3603–3610 (2004).
Lai, L. & Tan, T. M. Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem. J. 361, 497–503 (2002).
Van Aubel, R. A., Smeets, P. H., van den Heuvel, J. J. & Russel, F. G. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am. J. Physiol. Renal Physiol. 288, 327–333 (2005).
El-Sheikh, A. A., van den Heuvel, J. J., Koenderink, J. B. & Russel, F. G. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J. Pharmacol. Exp. Ther. 320, 229–235 (2007).
Bagley, C. M. Jr., Bostick, F. W. & DeVita, V. T. Jr. Clinical pharmacology of cyclophosphamide. Cancer Res. 33, 226–233 (1973).
Acknowledgements
This work was supported by a leading project for personalized medicine in Ministry of Education, Culture, Sports, Science and Technology, Japan. We express our heartfelt gratitude to Drs Michiaki Kubo and Yoichiro Kamatani for their constructive comments and suggestions. We express our gratefulness to Miss Kumi Matsuda for her outstanding technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Low, SK., Kiyotani, K., Mushiroda, T. et al. Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. J Hum Genet 54, 564–571 (2009). https://doi.org/10.1038/jhg.2009.79
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/jhg.2009.79
Keywords
This article is cited by
-
Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect
Clinical Pharmacokinetics (2022)
-
Effects of cyclophosphamide related genetic variants on clinical outcomes of adult hematopoietic cell transplant patients
Cancer Chemotherapy and Pharmacology (2022)
-
ABC transporter superfamily. An updated overview, relevance in cancer multidrug resistance and perspectives with personalized medicine
Molecular Biology Reports (2021)
-
Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients
Tumor Biology (2015)
-
Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer
Cancer Chemotherapy and Pharmacology (2015)